ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes

Expert Review of Neurotherapeutics
Robert E Davis, Christoph U Correll

Abstract

ITI-007 is an investigational drug being developed for schizophrenia and other neuropsychiatric/neurodegenerative diseases. ITI-007 has a unique pharmacological profile, combining potent 5-HT2a receptor antagonism with cell-type-specific dopamine and glutamate receptor modulation, plus serotonin reuptake inhibition. At dopamine-D2 receptors, ITI-007 acts as a post-synaptic antagonist and pre-synaptic partial agonist. Additionally, ITI-007 stimulates phosphorylation of glutamatergic NMDA-NR2B receptors, downstream of dopamine-D1 receptor intracellular signaling. Based on a large, placebo and risperidone controlled, Phase-II trial, ITI-007 60 mg was shown to be effective in reducing symptoms in patients with acutely exacerbated schizophrenia. The antipsychotic efficacy of ITI-007 60 mg in this patient population was confirmed in a recently completed Phase III study. ITI-007 was associated with minimal safety risk compared to risperidone (Phase II study) or placebo (both studies) for neuromotor disturbances, prolactin changes, weight gain and metabolic abnormalities. A second 6-week, placebo and risperidone-controlled Phase-III trial in acutely exacerbated schizophrenia is ongoing.

References

Sep 17, 2016·Drug Development Research·Nadja P MaricCedo Miljevic
Apr 27, 2017·Expert Opinion on Investigational Drugs·Sheng-Min WangChi-Un Pae
Dec 4, 2019·Expert Opinion on Pharmacotherapy·Pankhuri VyasJames Robert Brašić
Jan 9, 2020·JAMA Psychiatry·Christoph U CorrellKimberly E Vanover
Nov 20, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kimberly E VanoverDean F Wong
Jun 28, 2020·The Annals of Pharmacotherapy·Jessica GreenwoodJose A Rey

Citations

Jan 1, 1991·Schizophrenia Bulletin·R J Wyatt
Mar 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E F CoccaroJohn G Csernansky
Oct 26, 2000·The Journal of Nervous and Mental Disease·D M PurnineM P Carey
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gerard J MarekLawrence H Price
Jan 22, 2005·The Journal of Pharmacology and Experimental Therapeutics·Marion WittmannP Jeffrey Conn
Jun 22, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David M GardnerPaul Waraich
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiWFSBP Task Force on Treatment Guidelines for Schizophrenia
Nov 7, 2007·CNS Spectrums·Christoph U Correll
Mar 28, 2009·Schizophrenia Bulletin·Oliver D Howes, Shitij Kapur
Oct 29, 2009·JAMA : the Journal of the American Medical Association·Christoph U CorrellAnil K Malhotra
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·Christoph U Correll
Oct 7, 2010·The Journal of Clinical Psychiatry·John M Kane, Christoph U Correll
Dec 28, 2010·Trends in Molecular Medicine·Christoph U CorrellAnil K Malhotra
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Jul 12, 2011·Expert Opinion on Investigational Drugs·Bjørn H EbdrupBirte Glenthøj
Oct 20, 2011·Nature Reviews. Endocrinology·Marc De HertChristoph U Correll
Jan 6, 2012·The International Journal of Neuropsychopharmacology·Larry AlphsJohn M Kane
Feb 16, 2013·Expert Opinion on Investigational Drugs·Tiago A MestreSusan H Fox
Sep 14, 2013·Schizophrenia Research·Stephen R MarderJonathan Rabinowitz
Oct 8, 2013·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·John M KaneChristoph U Correll
Nov 22, 2013·Journal of Psychopharmacology·Joel Frohlich, John D Van Horn
Sep 23, 2014·Expert Opinion on Emerging Drugs·Luisa-Sophie KösterChristoph U Correll
Jun 5, 2015·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Christoph U CorrellMarc De Hert
Oct 8, 2015·Biological Psychiatry·Jeffrey A LiebermanKimberly E Vanover

Related Concepts

Presynaptic Membrane
Metabolic Process, Cellular
Study
Antipsychotic Effect
Thyroid Hormone Metabolism, Abnormal
Dopaminergic Agents
Receptor, Serotonin,5-HT2A
Phase 3 Clinical Trials
Schizophrenia
Serotonin Measurement

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here